Evidence map›Paper›PMID 32640015›Full record

ArticleThe Journal of infectious diseases2021

The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study.

Lene Ryom, Jens D Lundgren, Peter Reiss, Mike Ross, Ole Kirk, Christophe A Fux, Phillipe Morlat, Eric Fontas, Colette Smith, Stephane De Wit and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Risk ofJournal of fungi (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 9 countries.

Lene RyomRigshospitalet, University of Copenhagen, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen, Denmark.
Jens D LundgrenRigshospitalet, University of Copenhagen, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen, Denmark.
Peter ReissAmsterdam University Medical Centers (location AMC), Department of Global Health and Division of Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.
Mike RossAlbert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.
Ole KirkRigshospitalet, University of Copenhagen, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen, Denmark.
Christophe A FuxClinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland.
Phillipe MorlatUniversité de Bordeaux, Inserm U 897, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Eric FontasDepartment of Public Health, Nice University Hospital, Nice, France.
Colette SmithCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
Stephane De WitDivision of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Antonella d'Arminio MonforteDipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.
Wafaa El SadrICAP-Columbia University and Harlem Hospital, New York, New York, USA.
Camilla HatlebergRigshospitalet, University of Copenhagen, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen, Denmark.
Andrew PhillipsCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
Caroline SabinCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
Matthew LawKirby Institute, University of New South Wales, Sydney, Australia.
Amanda MocroftCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
London International Development Centre · GBUniversity of Copenhagen · DKAlbert Einstein College of Medicine · USHarlem Hospital Center · USKantonsspital Aarau · CHOspedale San Paolo · ITStichting HIV Monitoring · NLUniversité Côte d'Azur · FRUniversité de Bordeaux · FRUniversité Libre de Bruxelles · BEUNSW Sydney · AU

Funding

COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDSU01AI046362 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI GORDIN, FRED M · 2000 to 2006
$75.9M
The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
TERRY BEIRN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ONU01AI042170 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 1997 to 2006
$23.2M
Novel mechanisms of antiretroviral protection against HIV-related kidney diseasesR01DK101338 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROSS, MICHAEL J · 2014 to 2018
$1.9M
The role of APOL1 polymorphisms in promoting HIV-related kidney injuryR01DK108346 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROSS, MICHAEL J · 2015 to 2019
$1.6M
NIAID NIH HHS U01 AI042170NIAID NIH HHS U01 AI046362NIAID NIH HHS U01 AI069907NIDDK NIH HHS R01 DK101338NIDDK NIH HHS R01 DK108346
6 · The paper itself

Abstract

backgroundRelations between different measures of human immunodeficiency virus-related immunosuppression and chronic kidney disease (CKD) remain unknown.

methodsImmunosuppression measures included baseline, current, time-lagged and nadir CD4, years and percentage of follow-up (%FU) with CD4 ≤200 cells/μL, and CD4 recovery. CKD was defined as confirmed estimated glomerular filtration rate <60 mL/minute/1.73 m2.

resultsOf 33 791 persons, 2226 developed CKD. Univariably, all immunosuppression measures predicted CKD. Multivariably, the strongest predictor was %FU CD4 ≤200 cells/μL (0 vs >25%; incidence rate ratio [IRR], 0.77 [95% confidence interval [CI], .68-.88]), with highest effect in those at low D:A:D CKD risk (IRR, 0.45 [95% CI, .24-.80]) vs 0.80 [95% CI, .70-.93]).

conclusionsLonger immunosuppression duration most strongly predicts CKD and affects persons at low CKD risk more.

Indexed as

Immune ToleranceAdultCD4 Lymphocyte CountFemaleGlomerular Filtration RateHIV InfectionsHumansIncidenceMaleMiddle AgedProspective StudiesRenal Insufficiency, ChronicRisk FactorsCD4chronic kidney diseaseCKDeGFRHIVimmunosuppressionrenal

Identifiers

PMID32640015
PMCPMC7904289
OpenAlexW3041263729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.